{"entity":{"id":"idea-acc-ai-first-pathology-common-cases","kind":"idea","name":"AI-first reading for high-volume common cancer diagnoses, pathologist for the exceptions","aka":[],"tldr":"Let validated AI make the first read on routine, high-volume samples like cervical smears and standard breast biopsy stains, so scarce pathologists spend their time on the difficult cases.","summary":"Pathology AI is now good enough for narrow, high-volume tasks: cervical cytology screening, prostate biopsy detection, HER2 and ER scoring on breast biopsies. In systems with a fraction of the needed pathologists, an AI-first workflow with pathologist sign-off only on flagged or discordant cases could multiply capacity. The unsolved problems are local validation on different scanners and populations, regulatory acceptance in each jurisdiction, and liability.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (Most of the world has almost no cancer care): WHO fact sheet, Cancer","url":"https://www.who.int/news-room/fact-sheets/detail/cancer"}],"tags":[],"related":["idea-ai-her2-low-scoring"],"cancers":["cervical","breast-hr-positive"],"sections":[],"technologies":["digital-pathology-ai","pathology-foundation-model"],"targets":[],"drugs":[],"companies":["paige","pathai","lunit","owkin"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-global-access","b-workforce","b-ai-validation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"In a pathologist-scarce setting, an AI-first workflow will at least triple cases reported per pathologist-hour while keeping sensitivity for malignancy above 98% on prospective audit.","rationale":"AI cervical screening tools have already shown non-inferiority to cytotechnologists in several settings; the same triage logic is used for tuberculosis chest X-rays in high-burden countries.","test":"A prospective, paired-read study in two LMIC laboratories on cervical cytology and breast core biopsies: AI-first with sign-off versus full human read, measuring throughput, sensitivity, specificity, and time to report.","maturity":"early-clinical","actor":"data","cost":"medium","horizonYears":4},"route":"/ideas/idea-acc-ai-first-pathology-common-cases/","neighbours":{"idea":[{"id":"idea-ai-her2-low-scoring","kind":"idea","name":"AI quantification of HER2-low and HER2-ultralow","route":"/ideas/idea-ai-her2-low-scoring/"},{"id":"idea-acc-pathologist-assistants-and-ai-triage","kind":"idea","name":"Pathologist assistants plus AI triage to multiply pathologist capacity","route":"/ideas/idea-acc-pathologist-assistants-and-ai-triage/"}],"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"technology":[{"id":"digital-pathology-ai","kind":"technology","name":"Digital pathology & AI","route":"/technologies/digital-pathology-ai/"},{"id":"pathology-foundation-model","kind":"technology","name":"Pathology & radiology foundation models","route":"/technologies/pathology-foundation-model/"}],"company":[{"id":"lunit","kind":"company","name":"Lunit","route":"/companies/lunit/"},{"id":"owkin","kind":"company","name":"Owkin","route":"/companies/owkin/"},{"id":"paige","kind":"company","name":"Paige AI","route":"/companies/paige/"},{"id":"pathai","kind":"company","name":"PathAI","route":"/companies/pathai/"}],"bottleneck":[{"id":"b-ai-validation","kind":"bottleneck","name":"AI that is built but not validated or deployed","route":"/bottlenecks/b-ai-validation/"},{"id":"b-global-access","kind":"bottleneck","name":"Most of the world has almost no cancer care","route":"/bottlenecks/b-global-access/"},{"id":"b-workforce","kind":"bottleneck","name":"Not enough oncologists, nurses, pathologists, physicists","route":"/bottlenecks/b-workforce/"}],"roadmap":[{"id":"ai-oncology-roadmap","kind":"roadmap","name":"AI in oncology roadmap: pattern readers → foundation models → agents in the workflow","route":"/roadmaps/ai-oncology-roadmap/"}]}}